swisspartners Ltd. Makes New $479,000 Investment in Kintara Therapeutics, Inc. (NASDAQ:KTRA)

swisspartners Ltd. acquired a new position in shares of Kintara Therapeutics, Inc. (NASDAQ:KTRA) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 275,000 shares of the company’s stock, valued at approximately $479,000.

Separately, Envestnet Asset Management Inc. purchased a new position in shares of Kintara Therapeutics in the 1st quarter valued at $27,000. Institutional investors own 6.75% of the company’s stock.

KTRA traded up $0.04 on Friday, reaching $1.79. The company had a trading volume of 28 shares, compared to its average volume of 1,064,248. Kintara Therapeutics, Inc. has a 1 year low of $0.61 and a 1 year high of $3.35. The company has a market cap of $58.39 million, a PE ratio of -0.82 and a beta of 1.45. The stock’s 50-day simple moving average is $1.47.

Kintara Therapeutics (NASDAQ:KTRA) last posted its earnings results on Friday, May 14th. The company reported ($0.23) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.18) by ($0.05). As a group, analysts forecast that Kintara Therapeutics, Inc. will post -0.68 earnings per share for the current year.

About Kintara Therapeutics

Kintara Therapeutics, Inc, a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer.

Featured Story: If I purchase shares through a brokerage account, am I the holder of record?

Want to see what other hedge funds are holding KTRA? Visit to get the latest 13F filings and insider trades for Kintara Therapeutics, Inc. (NASDAQ:KTRA).

Institutional Ownership by Quarter for Kintara Therapeutics (NASDAQ:KTRA)

Receive News & Ratings for Kintara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kintara Therapeutics and related companies with's FREE daily email newsletter.